Paul Roepman
Papers
1
Total Citations
86
H-Index
1
About
Paul Roepman is a leading figure in the field of precision oncology, with his research squarely focused on the clinical implementation of whole genome sequencing (WGS) for cancer diagnostics. His most impactful work, the 2021 paper "Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics," which has garnered 86 citations, provides pivotal evidence that WGS using fresh-frozen tissue and matched blood samples can serve as the most comprehensive genetic tumor test available. Roepman’s major contribution lies in demonstrating how a single, all-inclusive test can replace the need for multiple, sequential biomarker assays—a crucial advancement as biopsies become smaller and the demand for multi-marker screening grows. This work directly addresses a critical bottleneck in oncology: efficiently extracting maximal actionable genetic information from limited tissue samples. By validating WGS’s clinical utility, Roepman has helped pave the way for its adoption as a standard-of-care diagnostic tool, promising more streamlined, cost-effective, and complete tumor profiling that can guide personalized treatment decisions for cancer patients.
Research Focus
Key Achievements
Top Papers
- 1Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics86 citations · 2021